Blood pressure targets for hypertension in people with diabetes mellitus

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 10, 2013, Pages

  Arguedas, Jose Agustin ^a   Leiva, Viriam ^b   Wright, James M ^c  

^a Rodrigo Facio University City   (Costa Rica)

^b UNIVERSIDAD DE COSTA RICA   (Costa Rica)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANGIONEUROTIC EDEMA; BRADYCARDIA; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SAFETY; END STAGE RENAL DISEASE; FAINTNESS; HEART ARRHYTHMIA; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INCIDENCE; INTERMEDIATE RISK PATIENT; KIDNEY FAILURE; LOW RISK PATIENT; MORTALITY RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; ADULT; BLOOD PRESSURE; DIABETIC ANGIOPATHIES; DIASTOLE; META ANALYSIS; MORTALITY; REFERENCE VALUE; STROKE; SYSTOLE; DIABETIC ANGIOPATHY;

ADULT; BLOOD PRESSURE; DIABETIC ANGIOPATHIES; DIASTOLE; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REFERENCE VALUES; STROKE; SYSTOLE;

EID: 84899468978     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008277.pub2     Document Type: Review

References (57)

1. Estacio RO, Coll JR, Tran ZV, Schrier RW. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. American Journal of Hypertension 2006;19(12):1241-8.
2. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff Sl, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. New England Journal of Medicine 1998;338(10):645-52.
3. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney International 2002;61(3):1086-97.
4. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. New England Journal of Medicine 2010;362(17):1575-85.
5. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt B, Julius S, et al.Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Stdy Group. Lancet 1998;351(9118):1755-62.
6. Anon. Hypertension in Diabetes Study IV. Therapeutic requirements to maintain tight blood presure control [Erratum]. Diabetologia 1997;40(3):366.
7. Hypertension in Diabetes Study Group. Hypertension in Diabetes Study IV. Therapeutic requirements to maintain tight blood presure control. Diabetologia 1996;39(12):1554-61.
8. Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ. Effect on intensive blood pressure control on the course of type 1 diabetic nephropathy. American Journal of Kidney Diseases 1999;34(5):809-17.
9. Howard BV, Roman MJ, Devereux RB, Fleg JL, Galloway JM, Henderson JA, et al.Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes. JAMA 2008;299(14):1678-89.
10. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine 2003;348(5):383-93.
11. Anon. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 [Erratum]. BMJ 1999;318(7175):29.
12. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317(7160):703-13.
13. Schrier RW, Estacio RO, Mehler PS, Hiatt WR. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. Nature Clinical Practice: Nephrology 2007;3(8):428-38.
14. Estacio RO, Gifford N, Jeffers BW, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(Suppl 2):B54-64.
15. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2012;35(Suppl 1):S11-63.
16. American Diabetes Association. Standards of medical care in diabetes 2013. Diabetes Care 2013;36(Suppl 1):S11-66.
17. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews CR, Cull CA, et al.Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321(7258):412-9.
18. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL Jr, et al.Treatment of hypertension in the prevention and management of ischemic heart disease. A scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007;115(21):2761-88.
19. Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD004349.pub2]
20. Arguedas JA. Blood pressure targets: are clinical guidelines wrong?. Current Opinion in Cardiology 2010;25(4):350-4.
21. Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, et al.J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. European Heart Journal 2010;31(23):2897-908.
22. Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose. Observations from traditional and Bayesian random-effects meta-analyses of randomized trials. Circulation 2011;123(24):2799-810.
23. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al.British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328(7440):634-40.
24. Boissel JP, Gueyffier F, Boutitie F, Pocock S, Fagard R. Apparent effect on blood pressure is only partly responsible for the risk reduction due to antihypertensive treatments. Fundamental & Clinical Pharmacology 2005;19(5):579-84.
25. Turnbull F, Blood Pressure Lowering Treatment Trialistś Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362(9395):1527-35.
26. Rabi DM, Daskalopoulou SS, Padwal RS, Khan NA, Grover SA, Hackam DG, et al.The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Canadian Journal of Cardiology 2011;27(4):415-33.
27. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al.Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010;304(1):61-8.
28. Deedwania PC. Blood pressure control in diabetes mellitus. Is lower always better, and how low it should go?. Circulation 2011;123(24):2776-8.
29. Dorresteijn JA, Van der Graaf Y, Spiering W, Grobbee DE, Bots ML, Visseren FL, Secondary Manifestations of Arterial Disease Study Group. Relation between blood pressure and vascular events and mortality in patients with manifest vascular disease. J-curve revisited. Hypertension 2012;59(1):14-21.
30. Mancia G, De Backer G, Domiiczak A, Cifkova R, Fagard R, Germano G, et al.2007 Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 2007;25(6):1105-87.
31. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al.2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal 2013;34(28):2159-219.
32. Farnett L, Mulrow CD, Linn WD, Lucey CR, Tuley MR. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous?. JAMA 1991;265(4):489-95.
33. Filippone EJ, Foy A, Newman E. Goal-directed antihypertensive therapy: lower may not always be better. Cleveland Clinic Journal of Medicine 2011;78(2):123-33.
34. Grossman E. Blood pressure: the lower, the better. The con side. Diabetes Care 2011;34(Suppl 2):308-12.
35. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
36. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
37. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al.The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 report. JAMA 2003;289(19):2560-72.
38. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996;275(20):1571-6.
39. Sánchez RA, Ayala M, Baglivo H, et al. Latin American Expert Group. Latin American Guidelines on Hypertension. J Hypertens 2009;27:905-22.
40. Laurent S. Guidelines from the British Hypertension Society. The lower the pressure the better. BMJ 2004;328(7440):593-4.
41. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al.Blood pressure, stroke and CHD. Part 1. Prolonged differences in blood pressure: prospective observational studies collected for the regression dilution blas. Lancet 1990;335(8692):765-74.
42. Mancia G, Grassi G, Zanchetti A. Antihypertensive treatment and blood pressure in diabetic and nondiabetic patients. The lower, the better?. Diabetes Care 2011;34(Suppl 2):304-7.
43. McBrien K, Rabi DM, Campbell N, Barnieh L, Clement F, Hemmelgarn BR, et al.Intensive and standard blood pressure targets in patients with type 2 diabetes mellitus. Systematic review and meta-analysis. Archives of Internal Medicine 2012;172(17):1296-303.
44. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, et al.Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?. Annals of Internal Medicine 2006;144(12):884-93.
45. National Institute for Health and Clinical Excellence. Hypertension. Clinical management of primary hypertension in adults. NICE clinical guideline 127 2011:1-36.
46. Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Annals of Internal Medicine 2003;139(9):761-76.
47. Parati G, Bilo G, Ochoa JE. Benefits of tight blood pressure control in diabetic patients with hypertension. Importance of early and sustained implementation of effective treatment strategies. Diabetes Care 2011;34(Suppl 2):S297-303.
48. Lewington S, Clarke R, Qisilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360(9349):1903-13.
49. Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P, et al. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73913 patients. Journal of Hypertension 2011;29(7):1253-69.
50. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
51. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, et al.Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial study. Journal of Hypertension 2009;27(7):1360-9.
52. Stamler J, Stamler R, Neaton JD. Blood Pressure, systolic and diastolic and cardiovascular risk. US population data. Archives of Internal Medicine 1993;153(5):598-615.
53. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
54. Vokó Z, Bots ML, Hofman A, Koudstaal PJ, Witteman JC, Breteler MM. J-shaped relation between blood pressure and stroke in treated hypertensives. Hypertension 1999;34(6):1181-7.
55. Whitworth JA, World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO/International Society of Hypertension (ISH) statement on management of hypertension. Journal of Hypertension 2003;21(11):1983-92.
56. Zanchetti A, Hansson L, Clement D, Elmfeldt D, Julius S, Rosenthal T, et al.HOT Study Group. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk-profiles: does a J-shaped curve exist in smokers?. Journal of Hypertension 2003;21(4):797-804.
57. Zanchetti A. Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced?. Journal of Hypertension 2009;27(8):1509-20.